Ori Spotlight

Ori Biotech
  • ٠٫٠ (٠)
  • علوم حياة
Ori Spotlight

Ori Spotlight covers the latest in cell and gene therapy. Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments. Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect

  1. Boro Dropulić: Simplifying CAR-T workflows will break down barriers to patient access

    قبل ٦ أيام

    Boro Dropulić: Simplifying CAR-T workflows will break down barriers to patient access

    In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Boro Dropulić, CEO of Vector Biomed and Executive Director at Caring Cross. Boro shares his vision of how decentralized manufacturing, low-cost vector production, and open-source workflows can make cell and gene therapies more accessible worldwide. They also discuss the role of digital technologies, partnerships, and innovative processes in overcoming industry bottlenecks, driving down costs, and expanding this access. Learn more about Boro on LinkedIn

    ٣٣ من الدقائق
  2. Michael Krajewski: How does the Theory of Constraints apply to CGT manufacturing?

    ٥ ربيع الآخر

    Michael Krajewski: How does the Theory of Constraints apply to CGT manufacturing?

    In this episode of the Ori Spotlight Podcast, Jason Foster is joined by Michael Krajewski, Director at Stand Back and an expert in engineering and scaling operations. Michael, with his background in aeronautics, brings a unique perspective on the Theory of Constraints and its role in CGT manufacturing processes. Michael and Jason dive into the complex dynamics of bottlenecks and discuss how understanding constraints can pave the way for growth – without compromising efficiency. Together, they explore how manufacturing lessons from other industries can address the limitations faced by cell therapy today, and what it takes to streamline complex, regulated processes. Learn more about Michael: https://www.linkedin.com/in/michael-krajewski/

    ١ س ١٠ د
  3. Carl Schoellhammer: viability is the crucial third pillar in CGT

    ١٩ ذو الحجة

    Carl Schoellhammer: viability is the crucial third pillar in CGT

    In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs). Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles. Learn more about Carl: https://www.linkedin.com/in/carl-schoellhammer/

    ٤٩ من الدقائق
  4. Anshul Mangal: Unlocking scale, automation, digitalization, and standardization in CGT

    ٢٧ ذو القعدة

    Anshul Mangal: Unlocking scale, automation, digitalization, and standardization in CGT

    In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Anshul Mangal, President at Project Farma, to discuss the hurdles to scalable CGT development, the importance of early strategic planning, and the role of digitalization in improving efficiency and reducing costs. Together they also highlight the potential of distributed manufacturing and the evolution of regulatory standards. Anshul Mangal is a biotech entrepreneur and executive, leading Project Farma and Precision for Medicine's Manufacturing Solutions. He has pioneered the industrialization of early cell and gene therapies. Anshul also serves on the boards of the Alliance for Regenerative Medicines, Alliance for mRNA Medicines, and IQHQ, driving advancements in next-generation medicines. Learn more about Anshul Mangal: https://www.linkedin.com/in/amangal/

    ١ س ٣ د
  5. Omkar Kawalekar: technology will unlock scalability and patient access

    ٦ ذو القعدة

    Omkar Kawalekar: technology will unlock scalability and patient access

    In this episode, Omkar Kawalekar of Deloitte's NextGenTherapies practice joins Ori CEO Jason C. Foster, to explore the significance of technology and strategic collaborations in overcoming manufacturing challenges and developing advanced therapies at scale. Their conversation covers key industry hurdles like supply chain optimization and the strategic planning necessary for bringing innovative treatments to market – offering insights into how the industry can achieve commercial viability and widespread patient access to CGTs. Learn more about Omkar: https://www.linkedin.com/in/omkar-kawalekar-7406887/

    ١ س ٨ د
  6. Joe DePinto: Bridging growth and accessibility within CGTs

    ١٣ شوال

    Joe DePinto: Bridging growth and accessibility within CGTs

    In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Joe DePinto, head of Cell and Gene Advanced Therapies at McKesson, to discuss challenges and innovations in cell and gene therapy manufacturing and supply chains. Together they also highlight the importance of collaborative partnerships and digital innovations to enhance access and streamline processes within the CGT sector. Joe DePinto is a strategic and operational leader at McKesson, focusing on establishing the company as a market leader in cell, gene, and advanced therapies. With an extensive background in biotech and pharmaceuticals, Joe has helped companies pioneer advanced solutions in speciality healthcare. Learn more about Joe DePinto: https://www.linkedin.com/in/joe-depinto-4a5b7b11/details/experience/

    ٤٧ من الدقائق
  7. Matthew Hewitt: scalability is a collective problem

    ١ رمضان

    Matthew Hewitt: scalability is a collective problem

    In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Matthew Hewitt, Vice President and Technical Officer of Cell and Gene Therapy and Biologics at Charles River Laboratories, to discuss why industry collaboration is needed to experience the true impact of advanced therapies and develop them at a commercial scale. Together they also highlight the role of technology in closing, automating and scaling manufacturing processes. Matthew has over 10 years of experience in the CGT sector, contributing to the advancement of CGTs across research and commercialization. As a member of our Strategic Advisory Board we're grateful for Matthew's insights as we work towards enabling widespread patient access to CGTs. Learn more about Matthew Hewitt: https://www.linkedin.com/in/matthewmhewitt/

    ١ س ٤ د
  8. Adam Siebert & Jeff Holder: early investment in manufacturing is critical for CGT accessibility

    ٩ شعبان

    Adam Siebert & Jeff Holder: early investment in manufacturing is critical for CGT accessibility

    In this episode of the Ori Spotlight Podcast, host Jason C. Foster is joined by Jeff Holder and Adam Siebert from LEK Consulting, who offer an in-depth exploration of the evolving cell and gene therapy (CGT) industry. LEK Consulting, a global leader in strategic advisory, aims to address the critical challenges of scalability and commercial viability within the CGT sector. Jeff and Adam, with their extensive background in life sciences consulting, share their insights on the importance of early investment in manufacturing processes to ensure that groundbreaking therapies can be delivered to patients efficiently and on a large scale. Together they explore the intricacies of CGT production, the significance of early-stage manufacturing considerations, and their vision for making advanced therapies more accessible to those in need. Learn more about: Jeff Holder - https://www.linkedin.com/in/jeff-holder-ph-d-7a391087 Adam Siebert - https://www.linkedin.com/in/adam-siebert-8772b327/

    ١ س ٦ د
مشاهدة الكل (٤١)

حول

Ori Spotlight covers the latest in cell and gene therapy. Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments. Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect

المعلومات

  • صناع العمل
    Ori Biotech
  • سنوات النشاط
    ١٤٤٢ هـ - ١٤٤٦ هـ
  • الحلقات
    ٤١
  • التقييم
    ملائم
  • حقوق النشر
    © Ori Biotech
  • موقع البرنامج على الويب
    Ori Spotlight

للاستماع إلى حلقات ذات محتوى فاضح، قم بتسجيل الدخول.

اطلع على آخر مستجدات هذا البرنامج

قم بتسجيل الدخول أو التسجيل لمتابعة البرامج وحفظ الحلقات والحصول على آخر التحديثات.
تحديد بلد أو منطقة

أفريقيا والشرق الأوسط، والهند

آسيا والمحيط الهادئ

أوروبا

أمريكا اللاتينية والكاريبي

الولايات المتحدة وكندا